Document is current
Any future updates will be listed below
-
Authors
Ito, Takahiro
Young, Michael J. https://orcid.org/0000-0002-9167-2413
Li, Ruitong
Jain, Sidharth https://orcid.org/0000-0002-6263-651X
Wernitznig, Andreas
Krill-Burger, John M. https://orcid.org/0000-0001-9614-4671
Lemke, Christopher T.
Monducci, Davide https://orcid.org/0000-0002-6761-1207
Rodriguez, Diego J. https://orcid.org/0000-0002-0053-8674
Chang, Liang
Dutta, Sanjukta https://orcid.org/0000-0002-8880-2192
Pal, Debjani https://orcid.org/0000-0002-3030-2590
Paolella, Brenton R. https://orcid.org/0000-0003-3394-828X
Rothberg, Michael V.
Root, David E. https://orcid.org/0000-0001-5122-861X
Johannessen, Cory M. https://orcid.org/0000-0002-2618-1036
Parida, Laxmi https://orcid.org/0000-0002-7872-5074
Getz, Gad https://orcid.org/0000-0002-0936-0753
Vazquez, Francisca https://orcid.org/0000-0002-2857-4685
Doench, John G. https://orcid.org/0000-0002-3707-9889
Zamanighomi, Mahdi
Sellers, William R. https://orcid.org/0000-0002-3539-9803
-
Funding
Funding for this research was provided by:
Ludwig Cancer Research at Harvard
Department of Defense Peer Reviewed Cancer Research Program Horizon Award
- License Information
-
More Information
Article History
Received: 11 August 2020
Accepted: 14 October 2021
First Online: 2 December 2021
Competing interests
: During the conduct of this research, W.R.S. was or is a Board or Scientific Advisory Board member and equity holder in Peloton Therapeutics, IDEAYA Biosciences, Civetta Therapeutics, Scorpion Therapeutics and Bluebird and has consulted for Array, Astex, Dynamo Therapeutics, Ipsen, PearlRiver Bio, Sanofi and Servier and receives research funding from Pfizer Pharmaceuticals, Merck, IDEAYA Biosciences and Deerfield Management. J.G.D. consults for Foghorn Therapeutics, Maze Therapeutics, Merck, Agios and Pfizer; he also consults for and has equity in Tango Therapeutics. D.E.R. receives research funding from Functional Genomics Consortium members AbbVie, Janssen, Merck and Vir. G.G. received research funding from IBM and Pharmacyclics and is a founder, consultant and holds private equity in Scorpion Therapeutics. T.I. is a current employee and equity holder of Scorpion Therapeutics. F.V. receives funding from Novo Ventures. C.M.J. is a current Novartis employee and stockholder. A.W. is a current employee of Boehringer Ingelheim. The other authors declare no competing interests.
